Surveillance of Anti-tuberculosis Drug Resistance in the World: an Updated Analysis, 2007-2010

Overview

Journal Bull World Health Organ

Specialty Public Health

Date 2012 Mar 17

PMID 22423162

Citations 112

Authors

Matteo Zignol

Wayne Van Gemert

Dennis Falzon

Charalambos Sismanidis

Philippe Glaziou

Katherine Floyd

Mario Raviglione

Affiliations

Soon will be listed here.

Abstract

Objective: To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010.

Methods: Data on drug resistance among new and previously treated TB patients, as reported by countries to the World Health Organization, were analysed. Such data are collected through surveys of a representative sample of TB patients or surveillance systems based on routine drug susceptibility testing. Associations between multidrug-resistant TB (MDR-TB) and human immunodeficiency virus (HIV) infection and sex were explored through logistic regression.

Findings: In 2007-2010, 80 countries and 8 territories reported surveillance data. MDR-TB among new and previously treated cases was highest in the Russian Federation (Murmansk oblast, 28.9%) and the Republic of Moldova (65.1%), respectively. In three former Soviet Union countries and South Africa, more than 10% of the cases of MDR-TB were extensively drug-resistant. Globally, in 1994 to 2010 multidrug resistance was observed in 3.4% (95% confidence interval, CI: 1.9-5.0) of all new TB cases and in 19.8% (95% CI: 14.4-25.1) of previously treated TB cases. No overall associations between MDR-TB and HIV infection (odds ratio, OR: 1.4; 95% CI: 0.7-3.0) or sex (OR: 1.1; 95% CI: 0.8-1.4) were found. Between 1994 and 2010, MDR-TB rates in the general population increased in Botswana, Peru, the Republic of Korea and declined in Estonia, Latvia and the United States of America.

Conclusion: The highest global rates of MDR-TB ever reported were documented in 2009 and 2010. Trends in MDR-TB are still unclear in most settings. Better surveillance or survey data are required, especially from Africa and India.

Citing Articles

Global burden of multidrug-resistant tuberculosis in children and adolescents.

Zhong Y, Xie H, Cai F, Liu M, Gan H, Tang Z Pediatr Res. 2025; .

PMID: 39934644 DOI: 10.1038/s41390-025-03917-1.

Population pharmacokinetics of bedaquiline: a systematic review.

Jin J, Cao J, Zhang R, Zheng L, Cai X, Li J Eur J Clin Pharmacol. 2025; 81(3):347-363.

PMID: 39779577 DOI: 10.1007/s00228-024-03788-1.

Structural Aspects of DNA Gyrase Targeted by Novel Bacterial Topoisomerase Inhibitors.

Kokot M, Hrast Rambaher M, Feng L, Mitchenall L, Lawson D, Maxwell A ACS Med Chem Lett. 2024; 15(12):2164-2170.

PMID: 39691510 PMC: 11647683. DOI: 10.1021/acsmedchemlett.4c00447.

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.

Patel M, Patel A, Nandpal M, Raval M, Patel R, Patel A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39377922 DOI: 10.1007/s00210-024-03466-0.

Epidemiology of multi-drug resistant Tuberculosis in the western region of Kenya.

Lugonzo G, Njeru E, Songock W, Okumu A, Ndombi E AIMS Microbiol. 2024; 10(2):273-287.

PMID: 38919722 PMC: 11194625. DOI: 10.3934/microbiol.2024014.

References

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F . Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11):1005-15. PMC: 2947799. DOI: 10.1056/NEJMoa0907847. View

Van Deun A, Wright A, Zignol M, Weyer K, Rieder H . Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis. 2011; 15(1):116-24. View

Moro M, Gori A, Errante I, Infuso A, Franzetti F, Sodano L . An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS. 1998; 12(9):1095-102. View

Barnard M, Albert H, Coetzee G, OBrien R, Bosman M . Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008; 177(7):787-92. DOI: 10.1164/rccm.200709-1436OC. View

Wright A, Zignol M, Van Deun A, Falzon D, Gerdes S, Feldman K . Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009; 373(9678):1861-73. DOI: 10.1016/S0140-6736(09)60331-7. View

Wells C, Cegielski J, Nelson L, Laserson K, Holtz T, Finlay A . HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007; 196 Suppl 1:S86-107. DOI: 10.1086/518665. View

Espinal M, Laszlo A, Simonsen L, Boulahbal F, Kim S, Reniero A . Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001; 344(17):1294-303. DOI: 10.1056/NEJM200104263441706. View

Abdel Aziz M, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A . Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006; 368(9553):2142-54. DOI: 10.1016/S0140-6736(06)69863-2. View

10.

Rigouts L, Hoza A, De Rijk P, Torrea G, Chonde T, Basra D . Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys. Int J Tuberc Lung Dis. 2011; 15(7):959-65. DOI: 10.5588/ijtld.10.0515. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Pablos-Mendez A, Raviglione M, Laszlo A, Binkin N, Rieder H, Bustreo F . Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998; 338(23):1641-9. DOI: 10.1056/NEJM199806043382301. View

13.

Seung K, Bai G, Kim S, Lew W, Park S, Kim J . The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis. 2003; 7(10):912-9. View

14.

Zignol M, Van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M . Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis. 2011; 52(7):901-6. PMC: 3062546. DOI: 10.1093/cid/cir081. View

15.

Cohn D, Bustreo F, Raviglione M . Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis. 1997; 24 Suppl 1:S121-30. DOI: 10.1093/clinids/24.supplement_1.s121. View

16.

Falzon D, Jaramillo E, Schunemann H, Arentz M, Bauer M, Bayona J . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38(3):516-28. DOI: 10.1183/09031936.00073611. View

17.

Edlin B, Tokars J, GRIECO M, Crawford J, Williams J, Sordillo E . An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992; 326(23):1514-21. DOI: 10.1056/NEJM199206043262302. View

18.

Suarez P, Watt C, Alarcon E, Portocarrero J, Zavala D, Canales R . The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001; 184(4):473-8. DOI: 10.1086/322777. View

19.

Abdel Aziz M, Wright A . The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis. 2005; 41 Suppl 4:S258-62. DOI: 10.1086/430786. View